Work

Global burden of HBV/HCV-related liver diseases, 1990–2021, and projections to 2050: A global burden of disease study 2021

Year: 2026
Type: article
Abstract: Despite the availability of measures to control hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related diseases, achieving elimination remains a substantial challenge. Effective action demands accurate assessment of the present and anticipation of the future. We utilized data from the Global Burden of Disease Study (GBD) 2021 to estimate the global burden of HBV- and HCV-related diseases for 204 countries and territories from 1990 to 2021. We defined HBV/HCV-related liver disease to include chronic hepatitis B, chronic hepatitis C, and cirrhosis attributable to chronic HBV or HCV. The burden was assessed using the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR), stratified by region, age, sex, and Socio-demographic Index (SDI). GBD estimates were reported with 95% uncertainty intervals (UIs); 1990 to 2021 percentage changes were calculated from point estimates. Forecasting analysis was conducted using the GBD 2021 forecast framework, supplemented by Das Gupta decomposition analysis. From 1990 to 2021, the global ASMRs of HBV- and HCV-related cirrhosis declined by 41.51% and 31.47%, respectively, while liver cancer-related ASMR showed divergent changes (HBV: -16.40%; HCV: +2.35%). ASDRs also declined across both cirrhosis and liver cancer (HBV: -42.07%, -22.34%; HCV: -29.34%, -8.24%). Regionally, the highest ASMRs for chronic hepatitis B and C including cirrhosis in 2021 were observed in Eastern Sub-Saharan Africa (14.51 per 1,00,000) and Central Sub-Saharan Africa (13.92 per 1,00,000), respectively. The burden of both viruses was generally higher in men. Age-specific mortality rates were highest in older age groups across HBV- and HCV-related liver diseases. By the late 2030s, the mortality burden of chronic hepatitis C is projected to surpass that of chronic hepatitis B, amid a slowing annual decline in the ASMR of chronic hepatitis C (-1.21% to -0.24%). Although the overall burden of HBV- and HCV-related liver diseases may decrease or stabilize, sustained progress hinges on equitable access to vaccination, optimized antiviral therapies, and a renewed global focus on HCV as its relative impact grows. Achieving meaningful reductions across SDI contexts will require not only scientific advances but also strategic efforts to improve affordability and distribution, supported by the political will to implement change.
Source: Medicine
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W7237211024
FWCI:
Cites: 41
Cited by:
Related to: 10